The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Effect of Acetazolamide on Visual Function in Patients With Idiopathic Intracranial Hypertension and Mild Visual Loss: The Idiopathic Intracranial Hypertension Treatment Trial
Open accessAbstract
IMPORTANCE: Acetazolamide is commonly used to treat idiopathic intracranial hypertension (IIH), but there is insufficient information to establish an evidence base for its use. OBJECTIVE: To determine whether acetazolamide is beneficial in improving vision when added to a low-sodium weight reduction diet in patients with IIH and mild visual loss. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, double-masked, placebo-controlled study of acetazolamide in 165 participants with IIH and mild visual loss who received a low-sodium weight-reduction diet. Participants were enrolled at 38 academic and private practice sites in North America from March 2010 to November 2012 and followed up for 6 months (last visit in June 2013). All participants met the modified Dandy criteria for IIH and had a perimetric mean deviation (PMD) between -2 dB and -7 dB. The mean age was 29 years and all but 4 participants were women. INTERVENTIONS: Low-sodium weight-reduction diet plus the maximally tolerated dosage of acetazolamide (up to 4 g/d) or matching placebo for 6 months. MAIN OUTCOMES AND MEASURES: The planned primary outcome variable was the change in PMD from baseline to month 6 in the most affected eye, as measured by Humphrey Field Analyzer. Perimetric mean deviation is a measure of global visual field loss (mean deviation from age-corrected normal values), with a range of 2 to -32 dB; larger negative values indicate greater vision loss. Secondary outcome variables included changes in papilledema grade, quality of life (Visual Function Questionnaire 25 [VFQ-25] and 36-Item Short Form Health Survey), headache disability, and weight at month 6. RESULTS: The mean improvement in PMD was greater with acetazolamide (1.43 dB, from -3.53 dB at baseline to -2.10 dB at month 6; n = 86) than with placebo (0.71 dB, from -3.53 dB to -2.82 dB; n = 79); the difference was 0.71 dB (95% CI, 0 to 1.43 dB; P = .050). Mean improvements in papilledema grade (acetazolamide: -1.31, from 2.76 to 1.45; placebo: -0.61, from 2.76 to 2.15; treatment effect, -0.70; 95% CI, -0.99 to -0.41; P < .001) and vision-related quality of life as measured by the National Eye Institute VFQ-25 (acetazolamide: 8.33, from 82.97 to 91.30; placebo: 1.98, from 82.97 to 84.95; treatment effect, 6.35; 95% CI, 2.22 to 10.47; P = .003) and its 10-item neuro-ophthalmic supplement (acetazolamide: 9.82, from 75.45 to 85.27; placebo: 1.59, from 75.45 to 77.04; treatment effect, 8.23; 95% CI, 3.89 to 12.56; P < .001) were also observed with acetazolamide. Participants assigned to acetazolamide also experienced a reduction in weight (acetazolamide: -7.50 kg, from 107.72 kg to 100.22 kg; placebo: -3.45 kg, from 107.72 kg to 104.27 kg; treatment effect, -4.05 kg, 95% CI, -6.27 to -1.83 kg; P < .001). CONCLUSIONS AND RELEVANCE: In patients with IIH and mild visual loss, the use of acetazolamide with a low-sodium weight-reduction diet compared with diet alone resulted in modest improvement in visual field function. The clinical importance of this improvement remains to be determined. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01003639.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A six-item short-form survey for measuring headache impact: The HIT-6™
Kosinski, M., Bayliss, M. S., Bjorner, J. B., Ware, J. E., Garber, W. H., Batenhorst, A., Cady, R., Dahlöf, C. G. H., Dowson, A., & Tepper, S. (2003) · Quality of Life Research · doi:10.1023/a:1026119331193 · Cited by 1,376
Psychometric Properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ)
Mangione, C. M. (1998) · Archives of Ophthalmology · doi:10.1001/archopht.116.11.1496 · Cited by 848
Swelling of the optic nerve head: a staging scheme
Frisen, L. (1982) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.45.1.13 · Cited by 492
The Idiopathic Intracranial Hypertension Treatment Trial: Clinical Profile at Baseline
Wall, M., Kupersmith, M. J., Kieburtz, K. D., Corbett, J. J., Feldon, S. E., Friedman, D. I., Katz, D. M., Keltner, J. L., Schron, E. B., & McDermott, M. P. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.133 · Cited by 481
Self-citationAnalyzing incomplete longitudinal clinical trial data
Molenberghs, G. (2004) · Biostatistics · doi:10.1093/biostatistics/5.3.445 · Cited by 463
The Production of Cerebrospinal Fluid in Man and Its Modification by Acetazolamide
Rubin, R. C., Henderson, E. S., Ommaya, A. K., Walker, M. D., & Rall, D. P. (1966) · Journal of Neurosurgery · doi:10.3171/jns.1966.25.4.0430 · Cited by 327
Scott, C. J. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.94 · Cited by 307
Johnson, L. N., Krohel, G. B., Madsen, R., & March, G. A. (1998) · Ophthalmology · doi:10.1016/s0161-6420(98)91234-9 · Cited by 264
Carbonic Anhydrase Inhibitor Side Effects: Serum Chemical Analysis
Epstein, D. L. (1977) · Archives of Ophthalmology · doi:10.1001/archopht.1977.04450080088009 · Cited by 191
Sun~er, I. J., Kokame, G. T., Yu, E., Ward, J., Dolan, C., & Bressler, N. M. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3225 · Cited by 170
Newborg, B. (1974) · Archives of Internal Medicine · doi:10.1001/archinte.133.5.802 · Cited by 129
Validation and Test Characteristics of a 10-Item Neuro-Ophthalmic Supplement to the NEI-VFQ-25
Raphael, B. A., Galetta, K. M., Jacobs, D. A., Markowitz, C., Liu, G. T., Nano-Schiavi, M. L., Galetta, S. L., Maguire, M. G., Mangione, C. M., GLOBE, D. R., et al. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.06.060 · Cited by 116
The Idiopathic Intracranial Hypertension Treatment Trial: Design Considerations and Methods
Friedman, D. I., McDermott, M., Kieburtz, K. D., Kupersmith, M. J., Stoutenburg, A., Keltner, J. L., Feldon, S. E., SCHRON, E. B., Corbett, J. J., & Wall, M. (2014) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000114 · Cited by 89
Self-citation
Cited by
Hampl, S. E., Hassink, S. G., Skinner, A. C., Armstrong, S. C., Barlow, S. E., Bolling, C. F., Avila Edwards, K. C., Eneli, I., Hamre, R., Joseph, M. M., et al. (2023) · Pediatrics · doi:10.1542/peds.2022-060640 · Cited by 1,389
Ferro, J. M., Bousser, M. ‐., Canhão, P., Coutinho, J. M., Crassard, I., Dentali, F., di Minno, M., Maino, A., Martinelli, I., Masuhr, F., et al. (2017) · European Journal of Neurology · doi:10.1111/ene.13381 · Cited by 749
Idiopathic intracranial hypertension: consensus guidelines on management
Mollan, S. P., Davies, B., Silver, N. C., Shaw, S., Mallucci, C. L., Wakerley, B. R., Krishnan, A., Chavda, S. V., Ramalingam, S., Edwards, J., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-317440 · Cited by 612
Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions
Markey, K. A., Mollan, S. P., Jensen, R. H., & Sinclair, A. J. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00298-7 · Cited by 537
The Idiopathic Intracranial Hypertension Treatment Trial: Clinical Profile at Baseline
Wall, M., Kupersmith, M. J., Kieburtz, K. D., Corbett, J. J., Feldon, S. E., Friedman, D. I., Katz, D. M., Keltner, J. L., Schron, E. B., & McDermott, M. P. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.133 · Cited by 481
Self-citation
Metadata
- Authors
- Wall, M., McDermott, M. P., Kieburtz, K. D., Corbett, J. J., Feldon, S. E., Friedman, D. I., Katz, D. M., Keltner, J. L., Schron, E. B., & Kupersmith, M. J.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2014-04-23
- Volume
- 311
- Issue
- 16
- Pages
- 1641
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2059438266
- Cited by
- 550
- References
- 13
- FWCI
- 27.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.